在循环林依赖性激酶4/6抑制剂进展后,定制先进乳腺癌治疗 - - 现实世界的数据分析
Marcin Kubeczko1, Anna Polakiewicz-Gilowska1, Katarzyna Świderska1
1Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Frontiers in oncology
|June 24, 2024
概括
在晚期乳腺癌中循环素依赖性激酶4/6抑制剂 (CDK4/6i) 进展后,量身定制的治疗显著改善了存活率. 中枢神经系统的进展是最糟糕的预后因素,需要进一步的研究以获得更好的结果.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 临床试验 临床试验
背景情况:
- 循环素依赖性激酶4/6抑制剂 (CDK4/6i) 是激素受体阳性,HER2阴性晚期乳腺癌的标准.
- 在CDK4/6i进展后最佳的治疗策略仍然是研究的关键领域.
- 确定预测和预后因素对于指导后续治疗至关重要.
研究的目的:
- 评估影响CDK4/6i进展后治疗结果的预测和预后因素.
- 为了比较量身定制的治疗策略与CDK4/6i衰竭后的标准疗法的疗效.
- 评估与不同治疗方法相关的生存益处.
主要方法:
- 对200名患有晚期乳腺癌的患者进行了回顾性分析,这些患者在CDK4/6i (2018-2024) 上进展.
- 随后的治疗方法分为"量身定制" (基于分子/基因发现或再剖析) 和"非量身定制" (内分泌疗法/仅化学疗法).
- 治疗组之间的无进展生存 (PFS) 和整体生存 (OS) 的比较.
主要成果:
- 中枢神经系统的进展被确定为最糟糕的预后因素.
- 接受量身定制治疗的患者与非量身定制治疗相比,PFS (13.5 vs. 4.9 个月) 和OS (未达到 vs. 11.5 个月) 的中位数显著更长.
- 12个月的PFS为54.1%的量身定制治疗,而非量身定制治疗为18.5%.
结论:
- 根据个体患者的个人形状,定制后续治疗策略对于改善长期结果至关重要.
- 在CDK4/6i进展后,预后仍然很差,特别是在中枢神经系统参与的情况下.
- 需要进行进一步的研究,以优化CDK4/6i失败后晚期乳腺癌的治疗模式.
关键词:
一个有着巨大的力量.晚期乳腺癌是什么?循环素依赖性激酶4/6抑制剂疾病的进展 疾病的进展这是palbocicliblib.ribocicliblib 的意思是什么意思提供量身定制的治疗.有针对性的治疗.更多相关视频
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
8.7K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
